IP Verse

Ready-To-Use Bortezomib Solution - EP3324937

The patent EP3324937 was granted to Stada Arzneimittel on Aug 17, 2022. The application was originally filed on Jul 21, 2016 under application number EP16744351A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3324937

STADA ARZNEIMITTEL
Application Number
EP16744351A
Filing Date
Jul 21, 2016
Status
Granted And Under Opposition
Jul 15, 2022
Grant Date
Aug 17, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ACCORD HEALTHCAREMay 17, 2023TER MEER STEINMEISTER & PARTNERADMISSIBLE
EXTROVISMay 16, 2023BREUERADMISSIBLE
NEDERLANDSCH OCTROOIBUREAUMay 16, 2023NEDERLANDSCH OCTROOIBUREAUADMISSIBLE
GRUNDMay 15, 2023GRUNDADMISSIBLE
STRAWMANMay 12, 2023VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBWITHDRAWN
CONSILIENT HEALTHApr 24, 2023ELKINGTON AND FIFEADMISSIBLE
EVER VALINJECTAug 18, 2022GASSNERADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTEP2644189
INTERNATIONAL-SEARCH-REPORTWO2013128419
INTERNATIONAL-SEARCH-REPORTWO2015025000
OPPOSITIONEA021179
OPPOSITIONEP2644189
OPPOSITIONUS2002169114
OPPOSITIONUS5780454
OPPOSITIONUS6713446
OPPOSITIONWO02059130
OPPOSITIONWO02059131
OPPOSITIONWO2009154737
OPPOSITIONWO2012121523
OPPOSITIONWO2013128419
OPPOSITIONWO2015025000
OPPOSITIONWO2017013208

Non-Patent Literature (NPL) Citations (53) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonym, "Gebrauchsinformation: Information für den Anwender VELCADE" 3,5 mg Pulver zur Herstellung einer Injektionslösung Bortezomib", (20140101), pages 1 - 13, XP093049075
OPPOSITION- Anonymous, "Bortezomib STADA® 2,5 mg/ml Injektionslösung Fachinformation", STADAPHARM, (20210601), pages 1 - 20, XP055956152
OPPOSITION- Anonymous, "Gebrauchsinformation: Information für den Anwender VELCADE® 3,5 mg Pulver zur Herstellung einer Injektionslösung Bortezomib", (20140000), pages 1 - 13
OPPOSITION- Anonymous, "GUIDELINE ON STABILITY TESTING: STABILITY TESTING OF EXISTING ACTIVE SUBSTANCES AND RELATED FINISHED PRODUCTS", European Medicines Agency Inspections, (20031217), European Medicines Agency Inspections, URL: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-stability-testing-stability-testing-existing-active-substances-and-related-finished-products-revision-1-corr_en.pdf, (20240301), XP093136629
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION VELCADE (bortezomib) for Injection", (20141001), pages 1 - 38, XP093062939
OPPOSITION- Anonymous, "ICH Topic Q 1 E Evaluation of Stability Data - NOTE FOR GUIDANCE ON EVALUATION OF STABILITY DATA (CPMP/ICH/420/02) ", European Medicines Agency - CPMP/ICH/420/02, (20030801), European Medicines Agency - CPMP/ICH/420/02 , URL: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-e-evaluation-stability-data-step-5_en.pdf, XP093163066
OPPOSITION- Anonymous, "NAME OF THE MEDICINAL PRODUCT - VELCADE 3.5 mg powder", pages 1 - 33
OPPOSITION- Anonymous, "Scottish Paediatric Retrieval Service Intravenous Medicine Information", Scottish Paediatric Retrieval Service Intravenous Medicine Information, (20080601), Scottish Paediatric Retrieval Service Intravenous Medicine Information, URL: https://www.snprs.scot.nhs.uk/SPRS%20Monograph%2014%2008%2006.pdf, XP093163071
OPPOSITION- Anonymous, "VELCADE ® 1 mg /-3,5 mg Pulver zur Herstellung einer Injektionslösung - Bortezomib - GEBRAUCHSINFORMATION: INFORMATION FÜR DEN ANWENDER", (20120301), URL: https://shop.ried-apotheken.de/images/ecommerce/00/82/00822831_2017-07_de_s.pdf, XP093195761
OPPOSITION- Anonymous, "VELCADE® (bortezomib) for Injection", Millennium Pharmaceuticals, Inc, (2006), pages 1 - 29
OPPOSITION- Anonymous, "VELCADE (bortezomib) for Injection PRESCRIBING INFORMATION", Millennium Pharmaceuticals, Inc, (20060301), pages 1 - 29, XP093049079
OPPOSITION- Anonymous, "VELCADE - Procedural steps taken and scientific information after the authorisation", European Medicines Agency (EMA), (20210101), European Medicines Agency (EMA), (20240301), XP093136634
OPPOSITION- ANONYMOUS, "Velcade® Summary of Product Characteristics", pages 1 - 32
OPPOSITION- Bolognese Adele, Et Al, "An NMR Study of the Bortezomib Degradation under Clinical Use Conditions", Advances in Hematology, (20090101), vol. e 704928, pages 1 - 5, XP093049061
OPPOSITION- Bortezomib stability study report (dated 23 October 2024)
OPPOSITION- Bortezomib STADA® PIL ( PL 00240/0432
OPPOSITION- Broadhead J, Gibson, M, "Chapter 9: Parenteral Dosage Forms", Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form, CRC Press, (20090101), vol. 199, pages 325 - 347, XP055882149
OPPOSITION- C. Hunnius, "Wasserstoffionenkonzentration", C. Hunnius, Curt Hunnius, Pharmazeutisches Wörterbuch, Walter de Gruyter, (19750101), pages 742 - 743, ISBN 3-11-001631-1, XP009551929
OPPOSITION- Claudia Brüchert, "Pufferung von Rezepturen", Deutsche Apotheker Zeitung, (20150101), pages 1 - 13, Deutsche Apotheker Zeitung, URL: https://www.deutsche-apotheker-zeitung.de/daz-az/2015/daz-35-2015/pufferung-von-rezepturen, (20220830), XP055956159
OPPOSITION- Ema, "VELCADE 1 mg powder for solution for injection. VELCADE® - SmPC (EU/1/04/274) ", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, (20140110), pages 1 - 51, ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, (20240123), XP093122558
OPPOSITION- EMEA, "Guideline on Stability Testing: Stability testing of Existing Active Substances and Related Finished Products", no. CPMP/QWP/122/02.REV 1, pages 1 - 18, URL: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-stability-testing-stability-testing-existing-active-substances-and-related-finished-products-revision-1-corr_en.pdf, (20080626), XP002662653
OPPOSITION- GARCIA et al., "Chemical stability of bortezomib solutions in original manufacturer vial at room temperature and in syringe at 4°C", UPBS, (20130000), vol. 3, no. 1, pages 449 - 458, XP093129271
OPPOSITION- Heiko Schiffter-Weinle, "Die Oxidation im Griff", Deutsche Apotheker Zeitung, (20160101), pages 1 - 14, Deutsche Apotheker Zeitung, URL: https://www.deutsche-apotheker-zeitung.de/daz-az/2016/daz-8-2016/die-oxidation-im-griff, (20220830), XP055956160
OPPOSITION- "ICH Topic Q U A (R2) Stability Testing of new Drug Substances and Products, Step 5, NOTE FOR GUIDANCE ON STABILITY TESTING: STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS (CPMP/ICH/2736/99)", European Medicines Agency, (20030801), pages 1 - 20, European Medicines Agency, URL: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002651.pdf, (20120216), XP055019637
OPPOSITION- John D. Ludwig, "Chapter 1: Parenteral dosage forms: introduction and historical perspective.", John D. Ludwig, Sandeep Nema, John D. Ludwig, Pharmaceutical dosage forms Teil: Parenteral medications, Vol. 1:, informa healthcare, (20100826), vol. 1, pages 1 - 5, ISBN 9781420086539, XP009554184
OPPOSITION- J. Sanchez-Rubio Ferrandez, "Extended stability of bortezomib", Hospital Pharmacy Europe, (20100323), Hospital Pharmacy Europe, URL: https://hospitalpharmacyeurope.com/news/editors-pick/extended-stability-of-bortezomib/, XP093163775
OPPOSITION- K.E. Avis, J. W. Levchuk, "Remington: The Science and Practice of Pharmacy, Chapter 41: Parenteral preparations", Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins , (20000101), pages 780 - 786, ISBN 978-0-683-30647-7, XP002728555
OPPOSITION- Linda Felton, THE SCIENCE AND PRACTICE OF PHARMACY, Pharmaceutical Press, (20130000), ISBN 978 0 85711 105 0
OPPOSITION- Michael J Akers, "Parenteral preparations", Michael J Akers, Linda A. Felton, Remington Essentials of pharmaceutics, Pharmaceutical Press, (20120101), pages 495 - 531, ISBN 978-0-85711-105-0, XP055222827
OPPOSITION- Morton Dana K, "Container /Closure Integrity of Parenteral Vials", Journal of Parenteral Science & Technology, (19870101), vol. 41, no. 5, pages 145 - 148, XP093176151
OPPOSITION- "Parenteralia", Anonymous, Europäisches Arzneibuch, 8. Ausgabe Grundwerk 2014 Band 1, Deutscher Apotheker Verlag , (20140101), pages V, 1196 - 1199, XP055956149
OPPOSITION- "ready-to-use", The Free Dictionary by Farlex, (20211123), URL: https://medical-dictionary.thefreedictionary.com/ready-to-use#:~:text=Able%20to%20be%20dispensed%20with
OPPOSITION- Rowe et al, "Mannitol", Handbook of Pharmaceutical Excipients, 7th edn., Pharmaceutical Press, (20120101), pages 479 - 482, Handbook of Pharmaceutical Excipients, 7th edn., URL: https://www.pharmpress.com/files/docs/Excipients7e_samplemonos(1).pdf, (20190318), XP002789781
OPPOSITION- Sarfaraz K. Niazi, "Frontmatter; Handbook of Pharmaceutical Manufacturing Formulations - Liquid Products", Sarfaraz K. Niazi, Sarfaraz K. Niazi, Handbook of Pharmaceutical Manufacturing Formulations - Liquid Products; Second Edition, informa healthcare, (20090921), pages i - xx, ISBN 978-1-4200-8123-7, XP009555979
OPPOSITION- "Table of Contents", Michael E. Aulton, Kevin M.G. Taylor, Aulton’s Pharmaceutics. The Design and Manufacture of Medicines (4th edition), Churchill Livingstone ; Elsevier , (20130101), ISBN 0-7020-4290-0, XP009559832
OPPOSITION- Voigt Rudolf, "Kapitel 20: Injektions- und Infusionszubereitungen", Voigt Rudolf, Voigt Rudolf, Pharmazeutische Technologie : für Studium und Beruf, Stuttgart, DE , Dt. Apotheker-Verl. , (20060101), pages 459 - 494, ISBN 978-3-7692-3511-1, XP093049534
OPPOSITION- Walker Scott E, Et Al, "Stability of Bortezomib 2.5 mg/mL in Vials and Syringes Stored at 4°C and Room Temperature (23°C)", CJHP, (20140401), vol. 67, no. 2, pages 102 - 107, XP093049530
OPPOSITION- WU et al., "Degradation pathways of a peptide boronic acid derivative, 2-Pyz-(CO)- Phe-Leu-B(OH)2", J. Pharm. Sci., (20000000), vol. 89, no. 6, doi:10.1002/(SICI)1520-6017(200006)89:6<758::AID-JPS7>3.0.CO;2-L, pages 758 - 765, XP001197158
OPPOSITION- WU S et al, "Degradation Pathways of a Peptide Boronic Acid Derivative, 2‐Pyz‐(CO)‐Phe‐Leu‐B(OH)2", Journal of Pharmaceutical Sciences, US , (20000601), vol. 89, no. 06, doi:10.1002/(SICI)1520-6017(200006)89:6<758::AID-JPS7>3.0.CO;2-L, ISSN 0022-3549, pages 758 - 765, XP001197158
OPPOSITION- WU S, WAUGH W, STELLA V J, "Degradation pathways of a peptide boronic acid derivative, 2-Pyz-(CO)-Phe-Leu-B(OH)(2)", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, US, US , (20000601), vol. 89, no. 06, doi:10.1002/(SICI)1520-6017(200006)89:6<758::AID-JPS7>3.0.CO;2-L, ISSN 0022-3549, pages 758 - 765, XP001197158
OPPOSITION- I Butler, ', Martin A A Schoonen ', David T Rickard ', "Removal of dissolved oxygen from water: A comparison of four common techniques", TALANTA, ELSEVIER, AMSTERDAM, NL, NL , (19940201), vol. 41, no. 2, doi:10.1016/0039-9140(94)80110-X, ISSN 0039-9140, pages 211 - 215, XP055449254
OPPOSITION- Navneeta Rajan, Habermehl Jason, Coté Marie-France, Doillon Charles J, Mantovani Diego, "Preparation of ready-to-use, storable and reconstituted type I collagen from rat tail tendon for tissue engineering applications", Nature Protocols, vol. 1, n. 6, doi:10.1038/nprot.2006.430, (20061201), pages 2753 - 2758, Nature Protocols, vol. 1, n. 6, URL: https://www.nature.com/articles/nprot.2006.430.pdf, (20200625), XP055708674
OPPOSITION- Micheal J Akers, "Drug Delivery: Prenteral Route", Micheal J Akers, James Swarbrick, Encyclopedia of Pharmaceutical Technology Third Edition Volume 1, Informa Healthcare, (20070101), pages 1266 - 1287, doi:10.1081/E-EPT-100000368, XP093087574
OPPOSITION- Gayle A. Brazeau , Adam Persky , Jintana Napaporn, "Dosage Forms: Parenterals", Gayle A. Brazeau , Adam Persky , Jintana Napaporn, James Swarbrick, Encyclopedia of Pharmaceutical Technology Third Edition Volume 1, Informa Healthcare, (20070101), pages 1001 - 1011, doi:10.1081/E-EPT-100001047, XP093087572
OPPOSITION- Allen C. Templeton , Robert A. Reed, "Headspace Oxygen Analysis in Pharmaceutical Products", Allen C. Templeton , Robert A. Reed, James Swarbrick, Encyclopedia of Pharmaceutical Technology Third Edition Volume 1, Informa Healthcare, (20070101), pages 1967 - 1976, doi:10.1081/E-EPT-120016552, XP093087576
OPPOSITION- CARATI et al., "Stability of bortezomib reconstituted under clinical use conditions in original vials and polypropylene syringes at 4°C and room temperature", European Journal of Hospital Pharmacy, (20120000), vol. 19, doi:10.1136/ejhpharm-2011-000041, pages 428 - 431, XP009551928
OPPOSITION- Lucena M, Barrueco Fernandez N, Gil Alegre Me, Escobar Rodriguez I, Lopez Lunar E, Garcia Diaz B, Ventura Valares Mg, "PP-022 Extended stability of 2.5 mg/ml bortezomib solution in syringes and opened vials", European journal of hospital pharmacy : EJHP, London : BMJ Group, England, England, (20140301), vol. 21, no. Suppl 1, doi:10.1136/ejhpharm-2013-000436.321, ISSN 2047-9956, pages A130 - A130, XP009554143
OPPOSITION- Bolognese Adele, Esposito Anna, Manfra Michele, Catalano Lucio, Petruzziello Fara, Martorelli Maria Carmen, Pagliuca Raffaella, Mazzarelli Vittoria, Ottiero Maria, Scalfaro Melania, Rotoli Bruno, "An NMR Study of the Bortezomib Degradation under Clinical Use Conditions", Advances in Hematology, Hindawi Publishing Corporation, (20090414), vol. 2009, doi:10.1155/2009/704928, ISSN 1687-9104, pages 1 - 5, XP093129221
OPPOSITION- Andre P; Cisternino S; Chiadmi F; Toledano A; Schlatter J; Fain O; Fontan J-E, "Stability of bortezomib 1-mg/mL solution in plastic syringe and glass vial", ANNALS OF PHARMACOTHERAPY, Harvey Whitney Books Company, US, US , (20050901), vol. 39, no. 9, doi:10.1345/aph.1E620, ISSN 1060-0280, pages 1462 - 1466, XP008113077
OPPOSITION- WALKER et al., "Stability of bortezomib reconstituted with 0.9% sodium chloride at 4°C and room temperature (23°C", Canadian Society Of Hospital Pharmacy, (20080101), vol. 61, no. 1, doi:10.4212/cjhp.v61i1.6, XP008113111
OPPOSITION- WALKER et al., "Stability of bortezomib reconstituted with 0.9% sodium chloride at 4°C and room temperature (23°C", Can J Hosp Pharm, (20080000), vol. 61, no. 1, doi:10.4212/cjhp.v61i1.6, pages 14 - 20, XP008113111
OPPOSITION- Walker S E; Milliken D; Law S, "Stability of bortezomib reconstituted with 0.9% sodium chloride at 4°C and room temperature (23°C)", CANADIAN SOCIETY OF HOSPITAL PHARMACY, (20080101), vol. 61, no. 1, doi:10.4212/cjhp.v61i1.6, ISSN 0008-4123, pages 14 - 20, XP008113111
OPPOSITION- Walker S E; Milliken D; Law S, "Stability of bortezomib reconstituted with 0.9% sodium chloride at 4°C and room temperature (23°C)", CANADIAN SOCIETY OF HOSPITAL PHARMACY, CANADIAN SOCIETY OF HOSPITAL PHARMACISTS, OTTAWA, (20080101), vol. 61, no. 1, doi:10.4212/cjhp.v61i1.6, ISSN 0008-4123, pages 14 - 20, XP008113111

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents